Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9172MR)

This product GTTS-WQ9172MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9172MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ925MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ4522MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ14327MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ15271MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ13599MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ3744MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ3529MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ866MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW